ZA922238B - Pyridazinone acetic acids. - Google Patents

Pyridazinone acetic acids.

Info

Publication number
ZA922238B
ZA922238B ZA922238A ZA922238A ZA922238B ZA 922238 B ZA922238 B ZA 922238B ZA 922238 A ZA922238 A ZA 922238A ZA 922238 A ZA922238 A ZA 922238A ZA 922238 B ZA922238 B ZA 922238B
Authority
ZA
South Africa
Prior art keywords
acetic acids
pyridazinone acetic
pyridazinone
acids
acetic
Prior art date
Application number
ZA922238A
Inventor
Banavara L Mylari
William J Zembrowski
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ZA922238B publication Critical patent/ZA922238B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30Phthalazines
    • C07D237/32Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA922238A 1991-03-28 1992-03-27 Pyridazinone acetic acids. ZA922238B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67691991A 1991-03-28 1991-03-28

Publications (1)

Publication Number Publication Date
ZA922238B true ZA922238B (en) 1993-09-27

Family

ID=24716565

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA922238A ZA922238B (en) 1991-03-28 1992-03-27 Pyridazinone acetic acids.

Country Status (19)

Country Link
EP (1) EP0582643A1 (en)
JP (1) JPH06500793A (en)
CN (1) CN1065269A (en)
AU (1) AU658887B2 (en)
BR (1) BR9205810A (en)
CA (1) CA2107104A1 (en)
CZ (1) CZ387092A3 (en)
DE (1) DE9290035U1 (en)
FI (1) FI934222A0 (en)
HU (1) HUT67836A (en)
IE (1) IE920979A1 (en)
IL (1) IL101325A0 (en)
MX (1) MX9201414A (en)
NZ (1) NZ242152A (en)
PT (1) PT100301A (en)
TW (1) TW207998B (en)
WO (1) WO1992017446A2 (en)
YU (1) YU30392A (en)
ZA (1) ZA922238B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2240657T3 (en) 2001-02-28 2005-10-16 Pfizer Products Inc. SULFONILPIRIDAZINONA COMPOUNDS USEFUL AS INHIBITORS OF ALDOSA REDUCTASA.
SE0100873D0 (en) * 2001-03-13 2001-03-13 Astrazeneca Ab Method of treatment
IL156462A0 (en) 2001-03-30 2004-01-04 Pfizer Prod Inc Pyridazinone aldose reductase inhibitors
AU761191B2 (en) * 2001-05-24 2003-05-29 Pfizer Products Inc. Therapies for tissue damage resulting from ischemia
US7572910B2 (en) 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
CN111617072B (en) * 2019-02-27 2023-06-20 苏州凯祥生物科技有限公司 Hyperuricemia medicine composition and medicine for treating hyperuricemia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0676391B2 (en) * 1987-06-09 1994-09-28 フアイザー・インコーポレイテツド Process for producing oxophthalazinyl acetic acid having heterocyclic side chain such as benzothiazole
FR2647676A1 (en) * 1989-06-05 1990-12-07 Union Pharma Scient Appl New pyridazinone derivatives, processes for preparing them and medicaments containing them which are useful, in particular, as aldose reductase inhibitors

Also Published As

Publication number Publication date
PT100301A (en) 1993-06-30
IL101325A0 (en) 1992-11-15
WO1992017446A2 (en) 1992-10-15
AU658887B2 (en) 1995-05-04
CZ387092A3 (en) 1994-02-16
MX9201414A (en) 1992-10-01
TW207998B (en) 1993-06-21
HUT67836A (en) 1995-05-29
CA2107104A1 (en) 1992-09-29
BR9205810A (en) 1994-06-28
HU9302728D0 (en) 1993-12-28
IE920979A1 (en) 1992-10-07
AU1779692A (en) 1992-11-02
YU30392A (en) 1994-11-15
NZ242152A (en) 1994-07-26
WO1992017446A3 (en) 1992-11-26
CN1065269A (en) 1992-10-14
FI934222A (en) 1993-09-27
EP0582643A1 (en) 1994-02-16
DE9290035U1 (en) 1993-11-18
JPH06500793A (en) 1994-01-27
FI934222A0 (en) 1993-09-27

Similar Documents

Publication Publication Date Title
EP0641203A4 (en) Imidazolyl-alkenoic acids.
AP9200447A0 (en) Acetic acid derivatives
ZA927377B (en) Dispersions.
AU1574892A (en) Novel pyridazines
ZA927955B (en) Cyclohexaneacetic acid derivatives.
ZA927129B (en) Soldering.
DE59204008D1 (en) Trachealstent.
ZA926482B (en) Cyanophenylpyrroles.
ZA927500B (en) Substituted imidazolyl-propenoic acid derivatives.
AU9137791A (en) Imidazolyl-alkenoic acids
ZA927792B (en) Anti-alpha6-integrin-antibodies.
AU1432092A (en) Quinoxaline phosphono-amino acids
ZA927501B (en) Imidazolyl-propenoic acid derivatives.
ZA929590B (en) Diphenylsulphides.
OA09716A (en) Benzoxaiole derivatives.
ZA929330B (en) Thiazolyl-substituted quinolylmethoxyphenylacetic acid derivatives.
ZA922238B (en) Pyridazinone acetic acids.
AU640328B2 (en) Sulfimidoperoxycarboxylic acids
EP0572573A4 (en) Thyroid-derived chondrocyte-stimulating factor.
ZA922061B (en) Peroxy acids.
DE69203865D1 (en) Thermo-transferdrucksystem.
DE69204801D1 (en) Hydroxy- oder oxosubstituierte alkylcyclopentene.
ZA929820B (en) Heisswinderschieber.
ZA929331B (en) Quinolylmethoxyphenyl-acetamides.
EP0570462A4 (en) MODIFIED INTERLEUKIN-1-g(b).